Distinguished Center Chooses Radixact Technology to Expand Range of Cancer Treatment Options, Raising the Bar for Other Centers Providing Radiotherapy
SUNNYVALE, California, Oct. 23, 2018 /PRNewswire/ -- Accuray Incorporated's (NASDAQ: ARAY) Radixact® System continues to penetrate the global radiotherapy market with its first installation in Turkey. Patients in Istanbul, Turkey will have a new cancer-fighting treatment option when clinicians at Anadolu Medical Center begin using the recently installed Radixact System. This next-generation helical radiotherapy system is replacing a conventional linear accelerator. With the addition of the Radixact System, Anadolu Medical Center will be the only facility in Turkey to offer patients treatment with both Accuray cutting-edge delivery systems -- the CyberKnife® System and the Radixact System.
The Radixact System is fully-integrated with the Accuray Precision® Treatment Planning System (TPS) and the iDMS™ Data Management System, enabling the clinical team to increase the ease and speed with which they deliver image-guided, intensity-modulated radiation therapy (IG-IMRT) treatments to virtually all patients across a broad range of indications. The CyberKnife platform specializes in delivering stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments with sub-millimeter precision.
"Radiotherapy is an important part of cancer treatment and using advanced technology, such as the Radixact System, aligns with our focus on putting patients first. We plan to treat a wide range of indications with the new system including craniospinal, head and neck, pelvic and breast cancers, as well as for total body irradiation," said Prof. Hale Başak Çağlar, radiation oncologist and radiation oncology director, Anadolu Medical Center. "We selected the Radixact System because its unique architecture facilitates the efficient delivery of highly-sculpted radiation doses to these types of indications. Additionally, the Accuray Precision TPS will enable us to generate high quality treatment plans for both the Radixact and CyberKnife Systems. We'll have the flexibility to treat patients using both systems, or to switch patients from one system to the other, providing us with more options in terms of how we treat each patient's cancer and really personalizing every treatment experience."
Learn more about what Prof. Çağlar has to say about the Radixact System here.
"Anadolu Medical Center is a reference center for Turkish cancer patients and an important destination for international cancer patients seeking high quality, up-to-date care. Cutting-edge technology is an important and indispensable part of the evidence-based advanced approach to the cancer treatment we offer," said Turkan Ozilhan Tacir, Chief Executive Officer at the Anadolu Medical Center. "Anadolu Medical Center is installing the first Radixact in Turkey as part of our comprehensive approach to cancer care. Our goal is to expand treatment options for both local and international cancer patients and provide them with the best possible care. Continually updating our equipment and services in order to offer the latest high-tech medical care, I feel proud to say that we are among the most technologically advanced hospitals in the world."
The Radixact System enables clinicians to deliver highly accurate, individualized dose distributions that precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for patients. A fully-integrated, streamlined adaptive treatment planning solution, PreciseART™ Adaptive Radiation Therapy Software, enables physicians to easily decide when adaptation of radiation delivery during the course of treatment would be beneficial due to changes in tumor size and patient anatomy.
"Turkey is at the forefront of a remarkable transformation in cancer care designed to improve the diagnosis and treatment of this potentially devastating disease," said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at Accuray. "We're proud that the Radixact System was chosen by Prof. Çağlar and the clinical team at Anadolu Medical Center to improve the lives of the cancer patients in their center. This high-throughput, full-body radiotherapy platform will enable them to provide best-in-class IG-IMRT treatments to more patients each day."
Anadolu Medical Center is a non-profit organization operating under the Anadolu Foundation and is focused on improving the quality of life for all patients seeking treatment. The center provides world-class health care in a caring and human centered environment. With the recent OECI (Organization of European Cancer Institutes) designation of Anadolu Medical Center as a Clinical Cancer Center, the organization has proved its distinguished level of excellence in cancer care in the region. Affiliated with Johns Hopkins Medicine, Anadolu Medical Center is recognized internationally for its ultramodern technology and top medical staff. The center provides services in Medical Oncology, Radiation Oncology, Gynecological Oncology, Hematological Oncology, Uro-oncology, Orthopedic Oncology, Head and Neck Oncology, Neuro-Oncology, Pulmonary Oncology, Gastrointestinal Oncology, Onco-Cardiology, Oncologic Imaging and Surgical Oncology.
About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's ability to continue to penetrate the global radiotherapy market, clinical applications, clinical results, and patient experiences and outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's limited long-term clinical data supporting the safety and efficacy of its products for certain users and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 24, 2018 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.